StockData
Candel Therapeutics, Inc. logo

Candel Therapeutics, Inc. (CADL) stock

CADLNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 1/30
$5.32−0.08 (-1.48%)

Close on Nov 18, 2026Market cap $407.08MP/E –Yield –

Candel Therapeutics pe ratio

The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.

No pe ratio figures for Candel Therapeutics

Candel Therapeutics has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

More Candel Therapeutics figures

See a number that looks wrong?